Glass House Brands (GLAS) Other Non-Current Assets (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Other Non-Current Assets of $435000.0 for Q1 2026, down 83.05% year-over-year from $2.6 million in Q1 2025, and down 58.96% quarter-over-quarter from $1.1 million in Q4 2025.
Glass House Brands (GLAS) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Other Non-Current Assets for 7 consecutive years, with $435000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 83.05% year-over-year to $435000.0; the TTM figure through Mar 2026 stood at $435000.0 (down 83.05% YoY), while the FY2025 annual figure was $1.1 million, down 64.67% from the prior year.
- Other Non-Current Assets declined to $435000.0 in Q1 2026 per GLAS's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.9 million in Q3 2024 and bottomed at $435000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $3.3 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 2187.6% — and 2026, when it plunged 83.05%.
- Glass House Brands' Other Non-Current Assets stood at $4.7 million in 2022, then slipped by 4.67% to $4.5 million in 2023, then tumbled by 32.93% to $3.0 million in 2024, then slumped by 64.67% to $1.1 million in 2025, then sank by 58.96% to $435000.0 in 2026.
- Business Quant data shows GLAS's Other Non-Current Assets at $435000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Glass House Brands | 833.73 Mn | 815.17 Mn | 15.77 Mn | 596,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.48 Mn |
| Dec 31, 2023 | 4.47 Mn |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Dec 31, 2022 | 4.69 Mn |
| Sep 30, 2022 | 3.67 Mn |
| Jun 30, 2022 | 3.63 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Dec 31, 2021 | 2.34 Mn |
| Sep 30, 2021 | 160,478.00 |
| Mar 31, 2021 | 431,409.00 |